Literature DB >> 27450275

Efficacy and safety of fractional Q-switched 1064-nm neodymium-doped yttrium aluminum garnet laser in the treatment of melasma in Chinese patients.

Baishuang Yue1, Qianli Yang1, Jinhua Xu1, Zhong Lu2.   

Abstract

Melasma is an acquired disorder of symmetrical hyperpigmentation commonly seen in patients with Fitzpatrick skin types III and IV. Various novel therapeutic modalities have emerged to treat melasma. The large-spot low-fluence QS Nd:YAG laser has been widely used in Asia; however, the modality needs to be optimized because of the high recurrence rate. The objective of this study is to explore the clinical efficacy and safety of fractional-mode (Pixel) Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) 1064-nm laser for treatment of melasma in Chinese patients. Twenty-seven patients were enrolled and completed all the treatment sessions and the 12-week follow-up. All were treated using the fractional-mode Pixel QS Nd:YAG (1064 nm) laser for eight sessions at a 2-3-week interval. Clinical photographs were taken using the Visia skin analysis imaging system. Two blinded assessors evaluated melasma area and severity index (MASI) scores before and 4 weeks after the final session. Melanin index (MI) and erythema index (EI) was measured before each treatment visit and after the final treatment. The degree of pigmentation and erythema was assessed using a tristimulus color analyzer. Physicians' global assessment (PGA) and patients' self-assessment were taken as the subjective assessments. Wilcoxon signed-rank test was performed to evaluate clinical response. Recurrence rate were also evaluated. Mean MASI scores decreased from 12.84 ± 6.89 to 7.29 ± 4.15 after treatment (p = 0.000). Seventy percent of patients got moderate to good improvements after all the treatment. Mean MI decreased significantly from 56.52 ± 23.35 to 32.75 ± 12.91 (p = 0.000). L value increased from 59.21 ± 2.22 before treatment to 61.60 ± 2.40 (p = 0.000) after therapy. The mean score of PGA was 3.76 ± 0.71, indicating a "moderate" clearance of the lesion. In patients' self-evaluations, 70 % of the patients rated the result as "good" to "remarkable." Partial recurrence was seen in 40 % patients at the 3-month follow-up. No severe adverse events were observed during the study, and the treatment was well tolerated. The fractional mode (Pixel) QS Nd:YAG 1064-nm laser is an effective and safe treatment for melasma. The recurrence rate was relatively lower than that reported in studies treating with large-spot low-fluence QS Nd:YAG laser.

Entities:  

Keywords:  1064-nm Nd:YAG laser; Fractional laser; Melasma

Mesh:

Substances:

Year:  2016        PMID: 27450275     DOI: 10.1007/s10103-016-2034-4

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  23 in total

1.  Defective barrier function in melasma skin.

Authors:  D J Lee; J Lee; J Ha; K-C Park; J-P Ortonne; H Y Kang
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-11-12       Impact factor: 6.166

2.  A low fluence Q-switched Nd:YAG laser modifies the 3D structure of melanocyte and ultrastructure of melanosome by subcellular-selective photothermolysis.

Authors:  Ji Young Mun; Se Yeong Jeong; Jae Hwan Kim; Sung Sik Han; Il-Hwan Kim
Journal:  J Electron Microsc (Tokyo)       Date:  2010-10-11

3.  Punctate leucoderma after melasma treatment using 1064-nm Q-switched Nd:YAG laser with low pulse energy.

Authors:  M J Kim; J S Kim; S B Cho
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-01-13       Impact factor: 6.166

Review 4.  Melasma: a comprehensive update: part I.

Authors:  Vaneeta M Sheth; Amit G Pandya
Journal:  J Am Acad Dermatol       Date:  2011-10       Impact factor: 11.527

Review 5.  Melasma: a comprehensive update: part II.

Authors:  Vaneeta M Sheth; Amit G Pandya
Journal:  J Am Acad Dermatol       Date:  2011-10       Impact factor: 11.527

6.  Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study.

Authors:  Marije W Kroon; Bas S Wind; Johan F Beek; J P Wietze van der Veen; Ludmila Nieuweboer-Krobotová; Jan D Bos; Albert Wolkerstorfer
Journal:  J Am Acad Dermatol       Date:  2011-01-20       Impact factor: 11.527

7.  Efficacy and safety of Q-switched 1,064-nm neodymium-doped yttrium aluminum garnet laser treatment of melasma.

Authors:  Xi Zhou; Michael H Gold; Zhong Lu; Ying Li
Journal:  Dermatol Surg       Date:  2011-05-26       Impact factor: 3.398

Review 8.  Melasma. Etiologic and therapeutic considerations.

Authors:  P E Grimes
Journal:  Arch Dermatol       Date:  1995-12

9.  Treatment of melasma by low-fluence 1064 nm Q-switched Nd:YAG laser.

Authors:  Ji Hoon Sim; Young Lip Park; Jong Suk Lee; Sung Yul Lee; Won Bok Choi; Hyun Jo Kim; Jung Hoon Lee
Journal:  J Dermatolog Treat       Date:  2013-02-24       Impact factor: 3.359

10.  The vascular characteristics of melasma.

Authors:  En Hyung Kim; You Chan Kim; Eun-So Lee; Hee Young Kang
Journal:  J Dermatol Sci       Date:  2007-03-23       Impact factor: 4.563

View more
  5 in total

Review 1.  Melasma: A Condition of Asian Skin.

Authors:  Michelle X Wu; Ruth Antony; Harvey N Mayrovitz
Journal:  Cureus       Date:  2021-04-10

Review 2.  A review of laser and light therapy in melasma.

Authors:  M K Trivedi; F C Yang; B K Cho
Journal:  Int J Womens Dermatol       Date:  2017-03-21

3.  Risk factors of striae gravidarum in Chinese primiparous women.

Authors:  Liping Liu; Jianling Huang; Ying Wang; Yumei Li
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

Review 4.  Melasma: an Up-to-Date Comprehensive Review.

Authors:  Oluwatobi A Ogbechie-Godec; Nada Elbuluk
Journal:  Dermatol Ther (Heidelb)       Date:  2017-07-19

5.  Clinical Evaluation of Sequential Transdermal Delivery of Vitamin B6, Compound Glycyrrhizin, Metronidazole, and Hyaluronic Acid Using Needle-Free Liquid Jet in Facial Seborrheic Dermatitis.

Authors:  Xiaomin Zhang; Bizhu Luo; Huihui Mo; Lexi Liao; Shuai Wang; Juan Du; Qiuting Liu; Yanhua Liang
Journal:  Front Med (Lausanne)       Date:  2020-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.